Nurix Therapeutics, Inc. (NRIX)
Health Care ยท Pharmaceutical Preparations
Nurix Therapeutics, Inc. (NRIX) is listed on Nasdaq, where its shares have traded since July 24, 2020. SentiSense covers Nurix Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Arthur T. Sands is its chief executive officer. The company reports 357 employees, and its corporate website is www.nurixtx.com.
About Nurix Therapeutics, Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 206 institutions reported holding NRIX, with 117.3 million shares worth $2.8 billion in aggregate. The largest reported holders were BlackRock, Vestal Point Capital and Deep Track Capital. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on NRIX
- NRIX sentiment: whether news and social coverage of Nurix Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- NRIX ownership: all 206 reporting institutions, plus insider and congressional trades.
- NRIX financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Nurix Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Nurix Therapeutics, Inc. do?
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases.
What sector is NRIX in?
SentiSense classifies Nurix Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does NRIX stock trade?
Nurix Therapeutics, Inc. (NRIX) is listed on Nasdaq, where its shares have traded since July 24, 2020.
Who is the CEO of Nurix Therapeutics, Inc.?
Arthur T. Sands is the chief executive officer of Nurix Therapeutics, Inc..